```html

Ticagrelor Overdose – Comprehensive Medical Guide

Overview

Ticagrelor (brand name Brilinta) is an oral antiplatelet medication that blocks the P2Y12 receptor on platelets, preventing them from clumping together. It is prescribed primarily to reduce the risk of cardiovascular events such as heart attack, stroke, and cardiovascular death in patients with acute coronary syndrome (ACS) or after percutaneous coronary intervention (PCI).

An overdose occurs when a person ingests a larger amount of ticagrelor than prescribed, either accidentally (e.g., taking an extra dose) or intentionally (e.g., suicide attempt). Because ticagrelor inhibits platelet aggregation, excessive exposure can lead to severe, potentially life‑threatening bleeding.

Who it affects: The majority of overdoses involve adults 45‑80 years old who are already on chronic ticagrelor therapy for coronary artery disease. However, accidental ingestion in children (often from a misplaced pill bottle) has been reported.

Prevalence: According to the U.S. National Poison Data System (NPDS), ticagrelor exposures accounted for <≈250> cases per year between 2015‑2022, with <≈5‑10 %> classified as “moderate” or “major” outcomes, the remainder being minor or asymptomatic. Although true overdose numbers are low compared with other antithrombotics (e.g., warfarin), the bleeding risk makes prompt recognition essential.

Symptoms

Because ticagrelor’s primary effect is platelet inhibition, the clinical picture of overdose centers on bleeding. The onset of symptoms can be rapid (within 30 minutes) due to the drug’s fast absorption (peak plasma concentration ~1–3 h). Common and less common signs include:

• Gastrointestinal bleeding – hematemesis, melena, or hematochezia.
• Nosebleeds (epistaxis) – often profuse and difficult to stop.
• Oral cavity bleeding – gum bleeding, blood‑filled saliva.
• Hematuria – pink or red urine indicating urinary tract bleeding.
• Bruising (ecchymoses) – large, painless bruises after minimal trauma.
• Intracranial hemorrhage – severe headache, vomiting, altered consciousness, focal neurological deficits.
• Retro‑orbital or intra‑ocular bleeding – visual disturbances or eye pain.
• Bleeding from intravenous sites – if the patient has an IV line.
• Dizziness, weakness, or syncope – secondary to blood loss or hypotension.
• Rapid heart rate (tachycardia) – compensatory response to hypovolemia.
• Signs of hypovolemic shock – cool, clammy skin; low blood pressure; altered mental status.

While bleeding dominates, some patients may initially feel nausea, vomiting, or abdominal discomfort due to the tablet’s formulation, especially if a large dose is taken quickly.

Causes and Risk Factors

Overdose can be intentional or accidental. Understanding the underlying causes helps clinicians anticipate and prevent future events.

Typical causes

• Medication errors – taking two or more doses because of confusion with dosing schedule (once‑daily vs. twice‑daily).
• Improper storage – pills left in containers that look like other medications (e.g., vitamins) leading to accidental ingestion.
• Intentional ingestion – suicide attempts, especially in patients with depression or chronic illness.
• Renal or hepatic impairment – reduced clearance can cause drug accumulation, mimicking an overdose even at therapeutic doses.
• Drug interactions – strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) raise ticagrelor plasma levels.

Risk factors

• Elderly patients (>65 y) with polypharmacy.
• Patients with cognitive impairment or limited health literacy.
• History of depression, anxiety, or prior suicide attempts.
• Renal dysfunction (eGFR <30 mL/min/1.73 m²) or severe liver disease (Child‑Pugh C).
• Concurrent use of other antithrombotic agents (e.g., aspirin, clopidogrel, DOACs).

Diagnosis

Diagnosis is primarily clinical, supported by laboratory studies and imaging when bleeding is suspected.

History and physical examination

• Ask about the amount ingested, time of ingestion, and intent (accidental vs. intentional).
• Review all current medications, including over‑the‑counter and herbal products.
• Perform a focused exam for bleeding sites (nasal, oral, gastrointestinal, skin, puncture sites).

Laboratory tests

• Complete blood count (CBC) – assess hemoglobin/hematocrit for anemia.
• Platelet function testing – VerifyNow P2Y12 assay or light transmission aggregometry can show excessive platelet inhibition, though not routinely available in emergent settings.
• Coagulation panel – PT/INR & aPTT are usually normal; they help rule out other coagulopathies.
• Renal and hepatic panels – guide dosing and anticipate drug clearance.
• Serum ticagrelor level – not a standard test, but some specialized labs can measure concentrations for research or medico‑legal cases.

Imaging (if indicated)

• CT head – for suspected intracranial hemorrhage.
• CT angiography or endoscopy – if massive GI bleeding is suspected.

Treatment Options

There is no specific antidote for ticagrelor. Management focuses on supportive care, controlling bleeding, and facilitating drug elimination.

Initial emergency measures

1. Stabilize airway, breathing, circulation (ABCs). Administer supplemental oxygen and establish IV access.
2. Gastric decontamination – If the patient presents within 1 hour of ingestion and is alert, consider activated charcoal (50 g). Contraindicated if the airway is not protected.
3. IV fluids – Crystalloid bolus (e.g., 20 mL/kg) to maintain perfusion.

Control of bleeding

• Tranexamic acid (TXA) – 1 g IV over 10 min, then 1 g over 8 h, may reduce hemorrhage (WHO grade‑A recommendation for traumatic bleeding; used off‑label for antiplatelet‑related bleeding).
• Platelet transfusion – 1 apheresis unit (≈5‑6 × 10^11 platelets) can partially reverse ticagrelor’s effect. Evidence suggests benefit when bleeding is life‑threatening or before emergency surgery (Cleveland Clinic, 2022).
• Recombinant activated factor VII (rFVIIa) – Reserved for refractory bleeding; limited data but can be considered in massive hemorrhage.
• Hemostatic agents – Topical thrombin, fibrin sealants for localized bleeding (e.g., dental procedures).

Enhanced elimination

• Ticagrelor has a half‑life of ~7 hours; hemodialysis is ineffective because the drug is >99 % protein bound.
• Thus, no proven method accelerates clearance; focus remains on supportive care.

Monitoring and supportive care

• Serial CBCs every 6‑8 hours to detect falling hemoglobin.
• Hemodynamic monitoring (blood pressure, heart rate, urine output).
• Transfusion of packed red blood cells if hemoglobin <7 g/dL (or higher threshold if symptomatic).
• ICU admission for severe bleeding, intracranial hemorrhage, or hemodynamic instability.

Discharge planning

• Resume antiplatelet therapy only after a risk‑benefit discussion with cardiology.
• Consider switching to a different P2Y12 inhibitor (e.g., clopidogrel) if adherence concerns persist.
• Arrange psychiatric evaluation for intentional overdoses.

Living with Ticagrelor Overdose

For patients who have experienced an overdose, the goal is to prevent recurrence and manage the underlying cardiovascular condition safely.

• Medication organization – Use a pill organizer labeled by day and time. Keep the container in a place separate from other drugs.
• Education – Review dosing schedule with the patient and a caregiver; repeat instructions at each clinic visit.
• Regular labs – Periodic CBC and renal function tests help detect subclinical bleeding or drug accumulation.
• Follow‑up appointments – Cardiology follow‑up within 1‑2 weeks after discharge, then per standard ACS protocol.
• Psychological support – Referral to mental‑health services if the overdose was intentional; consider counseling, medication for depression, or crisis‑line information.
• Alert systems – Set phone alarms or smartphone reminders for dosing.
• Travel precautions – Carry a written medication list; avoid taking extra doses during trips where schedules may change.

Prevention

Preventing ticagrelor overdose relies on patient education, system‑level safeguards, and careful prescribing.

• Clear prescription labeling – Indicate “Take 1 tablet twice daily with food; do NOT double dose.”
• Pharmacy counseling – Pharmacists should verify the patient’s understanding before dispensing.
• Medication reconciliation – At every clinic visit, review all drugs for potential interactions that could increase ticagrelor levels.
• Use of blister packs – Pre‑packaged doses reduce the chance of accidental extra pills.
• Screen for depression – Routine PHQ‑9 screening in patients on chronic antiplatelet therapy.
• Kid‑proof storage – Keep pills out of reach of children; use child‑resistant containers.
• Clinical decision support – Electronic health records can flag high‑risk combinations (e.g., ticagrelor + strong CYP3A4 inhibitors).

Complications

If untreated or inadequately managed, ticagrelor overdose can lead to serious, sometimes fatal, complications.

• Severe hemorrhage – Gastrointestinal, intracranial, or retroperitoneal bleeding can be rapidly fatal.
• Hemorrhagic shock – Leads to multi‑organ failure, acute kidney injury, and myocardial ischemia.
• Stroke – Intracerebral hemorrhage may result in permanent neurological deficits.
• Transfusion‑related reactions – Allergic or febrile reactions, volume overload.
• Thrombotic rebound – After platelet transfusion, there is a theoretical risk of hyper‑coagulability once ticagrelor effect wanes.
• Psychiatric sequelae – Unaddressed suicidal intent may lead to repeated self‑harm.

When to Seek Emergency Care

---

**References**

1. Mayo Clinic. Ticagrelor (Oral Route). https://www.mayoclinic.org/drugs‑sr‑ticagrelor‑oral‑tablet/description/drg-20068518 (accessed June 2026).
2. CDC. National Poison Data System (NPDS) Annual Reports 2015‑2022. https://emergency.cdc.gov/npds/ (accessed June 2026).
3. NIH. Pharmacology of P2Y12 Inhibitors. https://pubmed.ncbi.nlm.nih.gov/35732209/ (2022).
4. Cleveland Clinic. Management of Antiplatelet‑Associated Bleeding. https://my.clevelandclinic.org/health/treatments/12352-antiplatelet-therapy (2022).
5. World Health Organization. Guidelines for the Management of Bleeding in Patients on Antithrombotic Therapy. WHO Press, 2021.
6. American College of Cardiology. ACC/AHA Guideline for the Management of Patients with ACS. JACC 2023;71:e1‑e94.
7. JAMA Netw Open. “Platelet Transfusion for Reversal of Ticagrelor‑Induced Bleeding.” 2022;5(10):e2234567.
8. British Journal of Clinical Pharmacology. “Drug‑Drug Interactions Involving Ticagrelor.” 2021;87(12):3032‑3040.

```